Dr. Barth has more than 25 years of experience in drug development and most recently served as chief medical officer for Lexeo Therapeutics, a gene therapy company, according to a March 20 news release from Ascidian.
In his new role, Dr. Barth will lead clinical development across the company’s ophthalmology, neurological, neuromuscular and genetically defined diseases pipelines.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
